• 한국환경보건학회지
• /
• 제49권1호
• /
• pp.22-29
• /
• 2023

Background: The existing research results on the combined toxicity of these pollutants using mammals, such as rodents, are insufficient, especially in relation to changes in the immune system. Objectives: This study aims at evaluating the cellular immune response to PE-MPs solely or when combined with Pb, which possess excellent adsorption capacity with PE-MPs and is commonly co-exposed in our daily lives. Methods: The study investigated the cellular immune function of 9-week ICR mice with 28 days exposure to PE-MPs (2 mg/mouse/day) and Pb (0.1 mM in distilled water) individually and in combination. PE-MPs were administered via gastric intubation while the lead intake was conducted via the oral drinking water route. Cellular immunity was evaluated by analyzing the production for T_H1 cytokines namely, TNF-α and IFN-𝛾 and T_H2 cytokines, IL-4 and IL-6 in culture supernatants from polyclonally activated splenic mononuclear cells ex vivo. Results: Both the PE-MPs only and the PE-MPs+Pb exposure group revealed an increased T_H1 response with elevated TNF-α and IFN-𝛾 levels and downregulated T_H2 response with low IL-4, and IL-6 production levels compared to the control group. Furthermore, an increased IFN-𝛾/IL-4 ratio was found in the PE-MPs only and PE-MPs+Pb exposure groups, which indicated the skewedness to T_H1 response. Meanwhile, reduced blood hemoglobin levels and increased levels of IL-4, the dominant T_H2 cytokine in the Pb-only exposure group, were observed. Conclusions: Our current findings on the predominance of T_H1 immune response in the PE-MPs and PE-MPs+Pb groups suggest that PE-MPs could be responsible for the predominant induction of the cellular immune changes. This finding could be used as an important landmark in research related to T_H1 predominance, such as autoimmune diseases. It suggests that additional research on immune modulation using longer exposure durations or the same exposure route is required to elucidate stronger findings.

• 한국언어정보학회지:언어와정보
• /
• 제20권1호
• /
• pp.73-91
• /
• 2016

Korean adjectives in general cannot combine with measure phrases (MP), but MPs are compatible with adjectives when they appear with the inchoative morpheme -(e)ci. In this case, MPs can only denote the difference between two states along the dimension denoted by the root adjective. To account for this, this paper proposes that i) -(e)ci is a spell-out of V in the directed motion construction which takes an abstract path argument, like become, and ii) this path argument contains a comparative morpheme. By assuming this we can explain why MPs appear with -(e)ci, as well as other interesting phenomena such as variable telicity in deadjectival verbs with -(e)ci.

• 대한유전성대사질환학회지
• /
• 제15권3호
• /
• pp.160-164
• /
• 2015

Hunter syndrome(Mucopolysaccharidosis type II, MPS type II) is an X-linked disorder of glycosaminoglycans (GAGs) metabolism caused by an iduronate-2-sulfatase (IDS2) deficiency. A 24-month-old boy visited the department of pediatrics with the chief compliant of chronic purulent rhinorrhea beginning at age one. He had a history of repeated acute otitis media and chronic rhinitis. On physical examination he had a coarse face, enlarged tongue, distended abdomen, joint stiffness, and Mongolian spots at his first visit. The urine GAGs level was elevated at 66.10 mg/mmolCr (reference range, <11.1) and iduronate-2-sulfatase activity in leukocyte was decreased at 0.21 nmol/mg protein/hr (reference range, 18.7-57). Finally with an IDS gene mutational analysis, recombinant known mutation between intron 7 and distal of exon 3 in IDS2 was detected. Recombinant iduronate-2-sulfatase therapy was started without any infusion related reactions. The author highlights the importance of suspecting Hunter syndrome when pediatric patients visit with chronic purulent rhinorrhea which is a common cause of hospital visits for infants and children.

• Elastomers and Composites
• /
• 제27권1호
• /
• pp.20-26
• /
• 1992

Reactions between chlorinated or brominated poly(isobutylene-isoprene) (CIIR and BIIR, respectively) and 3-mercaptopropyltrimethoxysilane(MPS) were kinetically studied by gas chromatography in solution state. CIIR and BIIR were mixed with MPS and dibutyltin dilaurate as catalyst on roll mill and then the compounds were cured in hot water or atmosphere. From the gas chromatography, reaction order, activation energy, and frequency factor were determined. Crosslinking density and physical properties of moisture-cured CIIR and BIIR were measured. CIIR and BIIR were effectively moisture-cured and physical properties of these rubbers were comparatively good.

• Journal of Nutrition and Health
• /
• 제29권3호
• /
• pp.296-306
• /
• 1996

The ultimate aim of this study is to find high-fiber sources among Korean common foods and to develop a high-fiber supplement which can be useful in the therapeutic diet for the diabetic patients. For this purpose the effect of four kinds of seaweeds(mixture of purple laver & sea lettuce : MPS, sea tanle : ST, sea mustard : SM, agar agar : AA) on the glucose and lipid mtabolism were examined. Seven groups of normal and streptozotocin-induced diabetic rats were fed dietary fiber-free control diet or one of experimental diets containing 7% of one of four seaweeds for six weeks. The effects of seaweeds were campared with the effects of fiber-free diet or pectin diet. ST, SM, and AA showed a tendency of improving glucose tolerance improvement by those seaweeds, however, was less than that by pectin. MPS was found to possess a serum cholesterol-lowering effect which is comparable to that of pectin. All the supplementations of seaweeds induced significant increase in fecal steroids excretion. The amounts of fecal cholesterol excretion follwing in feeding of MPS and SM were as high as the level cause by pectin. The excretion of bile acids in the MPS group was much higher than that in the pectin group. Based on its effects of alleviating the diabetic symptoms in the previous study and of improving the glucose tolerance, sea mustard seems to have a benefical effect on glucose metabolism. The serum cholesterol-lowering effect of MPS possibly due to the significant increase in fecal steroids excretion suggests that MPS may be effective in improving abnormalities of lipid metabolism. Therefore, sea tangle and mixture of purple laver & sea lettuce seem to be promising as an effective source of high-fiber supplement for the diabetic patients.

• 대한소아치과학회지
• /
• 제39권4호
• /
• pp.412-417
• /
• 2012

뮤코다당증(mucopolysaccharidosis : MPS)은 glycosaminoglycans (GAGs)의 분해에 필요한 라이소좀 효소의 결함으로 인해 야기되는 질병으로 GAGs의 대사산물이 세포의 라이소좀 내에 축적되어 점차적으로 세포, 조직 그리고 기관의 기능 이상을 초래해 육체적, 정신적인 퇴행을 보이며, 심한 경우, 조기에 사망하게 되는 다양한 임상양상을 보이는 질환이다. 임상형은 어떠한 효소가 결핍되느냐에 따라 I형에서 IX형으로 분류한다. 치과적인 증상으로는 맹출 지연, 법랑질 저형성증, 왜소치, 부정교합, 하악 과두의 결함, 치은증식, 그리고 함치성낭 같은 여포성낭이 보고되었다. 뮤코다당증 환자는 심혈관계와 호흡계 기능이 취약하므로 치과 치료를 하는 경우, 전신 상태에 대한 주의사항과 뮤코다당증 환자에서 나타날 수 있는 구강 내 증상에 대해 미리 숙지하고, 의학적으로 환아의 전신 상태 변화에 민감하게 대처해가며 치과 진료를 시행해야 한다. 이 증례는 구강 내 다양한 임상증상을 보이는 제2형 뮤코다당증 환아의 치과 진료 후, 다소의 지견을 얻었기에 이를 보고하는 바이다.

• 대한유전성대사질환학회지
• /
• 제18권3호
• /
• pp.78-86
• /
• 2018

목적: 5명의 제2형 뮤코다당증 환자들의 임상적 스펙트럼과 효소대치요법의 단기간 치료 효과에 관해 알아 보고하고자 하였다. 방법: 5명의 환자들은 임상적 소견, 효소활성화 및 유전자검사에 의해 제2형 뮤코다당증으로 진단되었다. 이두설파제는 일주일 간격으로 0.5 mg/kg의 용량으로 정맥주사 주입을 하였으며, 효소대치요법 시작 전 후 12개월 이상 전신평가를 하였으며, 의무기록을 후향적으로 분석하였다. 결과: 3명의 환자들은 경증 유형, 2명의 환자들은 중증 유형의 제2형 뮤코다당증으로 진단되었다. 진단 시 중위연령은 9.6세(범위 3.4-26세)였다. 네 가계 중 다섯 명의 환자에서 4개의 서로 다른 유전자변이가 확인되었으며, 이중 두 개의 변이는 새로운 돌연변이였다(1개의 작은 삽입돌연변이: p.Thr409Hisfs*22, 1개의 과오돌연변이: p.Gly134Glu). 이중 동일한 유전자돌연변이를 지닌 두 명의 중중 유형의 형제 환자들은 서로 다른 임상적 특징들을 보였다. 12개월 간의 효소대치요법 후 소변 글리코사미노글리칸 배출은 유의하게 감소하였다(P=0.043). 간 및 비장의 용적은 모든 환자에서 유의하게 감소하였다(각각 P=0.043, P=0.043). 이외에도 좌심실질량지수(P=0.042), 어깨관절굽힘각도(P=0.043), 어깨관절벌림각도(P=0.039), 무릎관절굽힘각도(P=0.043), 팔꿉관절굽힘각도(P=0.042), 호흡장애지수(P=0.041)가 모두 호전된 소견을 보였다. 결론: 한국인 제2형 뮤코다당증 환자들은 임상적으로 다양한 특징을 보이며, 단기간의 이두설파제 치료는 주사주입관련 이상반응 없이 심장크기, 호흡장애지수를 포함한 여러 임상적 지표들의 호전에 효과적이었다.

• Journal of mucopolysaccharidosis and rare diseases
• /
• 제2권1호
• /
• pp.1-4
• /
• 2016

Mucolipidosis type II (MLII; MIM#252500) and type III alpha/beta (MLIIIA; MIM#252600) very rare lysosomal storage disease cause by reduced enzyme activity of GlcNAc-1-phosphotransferase. ML II is caused by a total or near total loss of GlcNAc-1-phosphotransferase activity whether enzymatic activity in patient with ML IIIA is reduced. While ML II and ML III share similar clinical features, including skeletal abnormalities, ML II is the more severe in terms of phenotype. ML III is a much milder disorder, being characterized by latter onset of clinical symptoms and slower progressive course. GlcNAc-1-phosphotransferase is encoded by two genes, GNPTAB and GNPTG, mutations in GNPTAB give rise to ML II or ML IIIA. To date, more than 100 different GNPTAB mutations have been reported, causing either ML II or ML IIIA. Despite development of new diagnostic approach and understanding of disease mechanism, there is no specific treatment available for patients with ML II and ML IIIA yet, only supportive and symptomatic treatment is indicated.

• 대한유전성대사질환학회지
• /
• 제14권1호
• /
• pp.29-36
• /
• 2014

Mucopolysaccharidoses (MPSs) are a group of rare inherited metabolic diseases caused by deficiency of lysosomal enzymes. MPSs are clinically heterogeneous and characterized by progressive deterioration in visceral, skeletal and neurological functions. The aim of this article is to review the treatment of MPSs, the unmet needs of current treatments and vision for the future including recent clinical trials. Until recently, supportive care was the only option available for the management of MPSs. Hematopoietic stem cell transplantation (HSCT), another potentially curative treatment, is not routinely advocated in clinical practice due to its high risk profile and lack of evidence for efficacy. From the early 2000s, enzyme replacement therapy (ERT) was approved and available for the treatment of MPS I, II and VI. ERT is effective for the treatment of many somatic symptoms, particularly walking ability and respiratory function, and remains the mainstay of MPS treatment. However, no benefit was found in the neurological symptoms because the enzymes do not readily cross the blood-brain barrier (BBB). In recent years, intrathecal (IT) ERT, substrate reduction therapy (SRT) and gene therapy have been rapidly gaining greater recognition as potential therapeutic avenues. Although still under investigation, IT ERT, SRT and gene therapy are promising MPS treatments that may prevent the neurodegeneration not improved by ERT.

• Clinical and Experimental Pediatrics
• /
• 제55권3호
• /
• pp.88-92
• /
• 2012

Purpose: Mucopolysaccharidosis type II (MPS II or Hunter syndrome) is a rare lysosomal storage disorder caused by iduronate-2-sulfatase (IDS) deficiency. MPS II causes a wide phenotypic spectrum of symptoms ranging from mild to severe. IDS activity, which is measured in leukocyte pellets or fibroblasts, was reported to be related to clinical phenotype by Sukegawa-Hayasaka et al. Measurement of residual plasma IDS activity using a fluorometric assay is simpler than conventional measurements using skin fibroblasts or peripheral blood mononuclear cells. This is the first study to describe the relationship between plasma IDS activity and clinical phenotype of MPS II. Methods: We hypothesized that residual plasma IDS activity is related to clinical phenotype. We classified 43 Hunter syndrome patients as having attenuated or severe disease types based on clinical characteristics, especially intellectual and cognitive status. There were 27 patients with the severe type and 16 with the attenuated type. Plasma IDS activity was measured by a fluorometric enzyme assay using 4-methylumbelliferyl- ${\alpha}$-iduronate 2-sulphate. Results: Plasma IDS activity in patients with the severe type was significantly lower than that in patients with the attenuated type ($p$=0.006). The optimal cut-off value of plasma IDS activity for distinguishing the severe type from the attenuated type was 0.63 $nmol{\cdot}4hr^{-1}{\cdot}mL^{-1}$. This value had 88.2% sensitivity, 65.4% specificity, and an area under receiver-operator characteristics (ROC) curve of 0.768 (ROC curve analysis; $p$=0.003). Conclusion: These results show that the mild phenotype may be related to residual lysosomal enzyme activity.